

Case Report

## Testicular metastasis of prostate adenocarcinoma: the other side of orchiepididymitis

Gianluca Di Rienzo<sup>1\*</sup>, Alessandro Tafuni<sup>1\*</sup>, Umberto Maestroni<sup>2</sup>, Livia Ruffini<sup>3</sup>, Enrico Maria Silini<sup>1</sup>, Donatello Gasparro<sup>4</sup>, Francesco Paolo Pilato<sup>1</sup>, Letizia Gnetti<sup>1</sup>

<sup>1</sup>Anatomic Pathology Unit, University Hospital of Parma, Parma, Italy; <sup>2</sup>Urology Division, University Hospital of Parma, Parma, Italy; <sup>3</sup>Nuclear Medicine Division, University Hospital of Parma, Parma, Italy; <sup>4</sup>Oncology Division, University Hospital of Parma, Parma, Italy

\*Authors contributed equally

### Summary

**Background.** Metastatic prostate adenocarcinoma is a rare event and there are few references to this topic. We report an unusual case of prostate cancer metastasis and review of contemporary literature. Moreover, we discuss the pathogenesis and the clinical aspects of this event.

**Case presentation.** A 70-year-old patient was admitted to the hospital for right scrotal pain. The ultrasound examination described an increase in testicular size, suggesting the possibility of orchiepididymitis. Past medical history reported a previous prostate adenocarcinoma. Inflammatory blood tests were normal. Importantly, PSA was 3.3 ng/ml. PET scan positivity in the scrotum raised suspicion of a relapse. Therefore, he underwent right orchiectomy.

**Conclusion.** Although metastatic prostate adenocarcinoma is rare, a correct diagnosis is of paramount importance because the therapy changes accordingly. Patients who complain of scrotal pain need to be examined accurately. Although the most common cause behind this symptom is infectious, the patient's past medical history should be reviewed to exclude previous malignancies.

### Background

Scrotal pain is a common reason for visits to the emergency room in adults. This symptom may be due to orchiepididymitis, testicular torsion, inguinal hernia or testicular neoplasm <sup>1</sup>.

Metastases to the testis are rare events. The most common metastatic neoplasm is leukemia; reported solid neoplasms are less frequent and include melanoma, prostate, lung and kidney adenocarcinomas. However, the incidence of this latter group is below 1% <sup>2,3</sup>.

We report the case of a man who was admitted to the hospital for scrotal pain; ultrasound examination showed an increase in testis size, and thus the patient underwent right orchiectomy. Surprisingly, the histology report revealed the presence of prostate adenocarcinoma.

### Case presentation

A 70-year-old patient was admitted to the emergency room of our hospital for right scrotal pain. He had no significant past medical history ex-

Received: October 23, 2023  
Accepted: February 14, 2024

#### Correspondence

Letizia Gnetti  
E-mail: letizia.gnetti@gmail.com


**How to cite this article:** Gianluca Di Rienzo G, Alessandro Tafuni A, Umberto Maestroni. Testicular metastasis of prostate adenocarcinoma: the other side of orchiepididymitis. *Pathologica* 2024;116:69-74. <https://doi.org/10.32074/1591-951X-940>

© Copyright by Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology



OPEN ACCESS

This is an open access journal distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license: the work can be used by mentioning the author and the license, but only for non-commercial purposes and only in the original version. For further information: <https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>



**Figure 1.**  $^{68}\text{Ga}$ -PSMA PET/CT in the restaging of prostate adenocarcinoma. MIP images (A); CT and fused PET/CT axial sections (B, C); CT and fused PET/CT coronal sections (D, E). PSMA PET/CT showed increased uptake in the right scrotum (black and light blue arrows) with SUVmax value of 5.6.

cept for a previous transurethral resection of the prostate (TURP) that led to the diagnosis of prostate adenocarcinoma (Gleason Score 9, Grade Group 5) six years earlier. The patient was treated with androgen deprivation therapy (leuprorelin) and radiotherapy. After hospital admission an ultrasound examination of the pelvic region was performed. It reported an increase in right testis size (46 x 22 mm), hydrocele, heterogenous echotexture and enhanced vascularity. Physical examination of the right testis showed swelling, hardness and soreness. Abdominal examination was unremarkable. The clinical presentation was suggestive of orchiepididimitis.

Blood tests were normal, except for PSA which was 3.3 ng/ml. Therefore, disease restaging was performed using positron emission tomography/computed tomography (PET/CT) with  $^{68}\text{Ga}$ -PSMA. The radiopharmaceutical was prepared in the local radiopharmacy as previously described <sup>4</sup>.


PSMA PET/CT revealed increased tracer accumulation in the right scrotum (SUVmax = 5.6) suggesting prostate cancer recurrence (Fig. 1).

The patient underwent right orchiectomy. The gross

description reported that the testis measured 5 x 3 x 2 cm, featured an area of induration and was diffusely gray on cut sections (Fig. 2A). The histology report described that most testis and epididymis were replaced by a glandular neoplasm with nests of plasmacytoid cells (Fig. 2B). Previous prostate adenocarcinoma was comparable to the testicular neoplasm (Fig. 2C). Immunohistochemistry showed that the tumor in the biopsy was positive to ERG (Fig. 2D), PSA (Fig. 2E) and AR (Fig. 2F), negative to inhibin, p63 and ER. The lesion in the testis was positive to PSMA (Fig. 2G), thereby suggesting metastatic prostate adenocarcinoma in the testis. To confirm the primary site, NKX3.1 was performed on the metastasis because it is considered both a sensitive and specific marker for prostate adenocarcinoma <sup>5</sup>. Figure 2H shows positivity in tumor cells.

## Discussion

A metastasis in the testis is a rare event. The incidence is below 1% except for leukemia and lympho-



**Figure 2.** Transurethral resection of the prostate (TURP) specimen and testis with prostate adenocarcinoma. Gross photograph of the testis (A); whole slide image of testicular metastasis at 4x (B); TURP specimen with prostate adenocarcinoma at 10x (C); ERG expression in the TURP specimen at 10x (D); PSA expression in the TURP specimen at 10x (E); androgen receptor expression in the TURP specimen at 10x (F); PSMA expression in the testicular metastasis at 4x (G); NKX3.1 expression in the testicular metastasis at 4x (H).

ma<sup>2</sup>. The likely explanation is that scrotal temperature prevents tumor cell proliferation. The risk of metastasis might also be reduced by the presence of Sertoli cells tight junctions, which constitute the blood-testis barrier<sup>6,7</sup>.

A palpable unilateral nodule is the clinical presentation of metastasis to the testis. However, testicular metastasis is often an incidental finding during specimen processing or autopsy. Both testes might be involved, but it is usually unilateral<sup>6,8</sup>. The interval between the event and the metastasis may range from six months to some years<sup>9</sup>. Metastatic prostate cancer usually has a high Gleason score which matches the primitive neoplasm<sup>6</sup>. Table I shows literature cases of prostate adenocarcinoma metastatic to the testis.

Metastatic high grade prostate adenocarcinoma should be differentiated from primary tumors of the testis. The International Society of Urological Pathology (ISUP) suggests performing the following antibodies: SALL4, OCT4 and EMA; alternatively, OCT4, Glypican 3, EMA and cytokeratin 7 might be used<sup>10</sup>.

Patient survival is limited to one year, despite reports of longer periods. Prognostic significance is uncertain. Both increase in PSA levels and PSMA PET/CT positivity should improve surveillance in hormone-treated

patients, especially to detect isolated metastases as in our patient<sup>9</sup>.

The best treatment following surgery is still a matter of debate. A single testicular metastasis might have a low risk of spreading to other organs, but this cannot be excluded. Therefore, orchiectomy may be followed by adjuvant therapy, which is based on radiotherapy or hormone therapy<sup>9</sup>. The latter includes androgen pathway inhibitors such as abiraterone and androgen receptor antagonists such as apalutamide and enzalutamide<sup>11</sup>.

Olaparib, a poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor, may be used in case of progression with hormonal agents on condition that patients have alterations in BRCA1 or BRCA2. For this reason, we suggest that metastatic prostate cancer be screened for these two mutations<sup>12</sup>.

## Conclusion

Patients who complain about scrotal pain need to be examined accurately. Although the most common cause behind this symptom is infectious, the patient's past medical history should be reviewed to exclude previous malignancies.

**Table I.** Literature cases of prostate adenocarcinoma metastatic to the testis.

Year	Authors	Age	PSA (ng/ml) at diagnosis	Histological type	GS	Time between diagnosis and metastasis in the testis (months)		Presentation in the testis	Involvement	Sides	PSA (ng/ml) at metastasis in the testis	Orchiectomy	ADT	RT	CT
						diagnosis	metastasis								
2018	Su et al. <sup>13</sup>	72	129	Acinar	9	6	Swelling	Bilateral	Both	Both	6.2	Yes	Yes	No	No
2016	Hsieh et al. <sup>14</sup>	62	NA	NA	NA	84	Induration	Unilateral	Right	Right	NA	Yes	Yes	Yes	No
2021	Olorunsola et al. <sup>6</sup>	71	6.8	Acinar	10	0	None	Bilateral	Both	Both	NA	Yes	Yes	No	No
2006	Manikandan et al. <sup>15</sup>	56	1100	Acinar	6	30	Swelling	Bilateral	Both	Both	60	Yes	Yes	No	No
2017	Santos-Lopes et al. <sup>16</sup>	69	NA	Acinar	8	60	Nodule	Unilateral	Left	Left	20	Yes	No	Yes	No
2015	Sampathrajan et al. <sup>17</sup>	63	225.5	Acinar	8	0	None	Unilateral	Right	Right	NA	Yes	No	No	No
2019	Bilal et al. <sup>18</sup>	55	100	NA	NA	0	None	Unilateral	Left	Left	NA	Yes	No	No	No
2019	Dahiru et al. <sup>19</sup>	82	25.8	Acinar	5	0	None	Unilateral	Left	Left	NA	Yes	No	No	No
2023	Kato et al. <sup>20</sup>	73	4.3	Acinar	8	28	Swelling	Unilateral	Left	Left	1.5	Yes	Yes	No	Yes
1997	Baykal et al. <sup>21</sup>	64	80	Acinar	5	0	None	Unilateral	Right	Right	NA	Yes	No	No	No
2015	Aydogmus et al. <sup>22</sup>	69	33.1	Acinar	9	0	Swelling	Unilateral	Left	Left	NA	Yes	No	No	No
2016	Campara et al. <sup>23</sup>	48	597	Acinar	7	108	Swelling	Unilateral	Left	Left	23.1	Yes	Yes	Yes	No
2009	Haupt et al. <sup>24</sup>	71	NA	Acinar	9	48	Nodule	Unilateral	NA	NA	NA	Yes	Yes	Yes	No
2022	DiMarco et al. <sup>25</sup>	67	3.3	Acinar	6	144	Swelling	Unilateral	Right	Right	0.3	Yes	No	No	No
2023	Hermi et al. <sup>26</sup>	55	100	Acinar	10	6	Induration	Unilateral	Left	Left	3.2	Yes	Yes	No	No
2018	Gao et al. <sup>27</sup>	69	100	Acinar	8	24	Swelling	Unilateral	Left	Left	19.2	Yes	Yes	No	No
2011	Kim et al. <sup>28</sup>	73	10.8	Acinar	6	96	None	Bilateral	Both	Both	9.3	Yes	Yes	No	No
2016	Zhang et al. <sup>29</sup>	69	100	Acinar	6	0	Swelling	Unilateral	Right	Right	NA	Yes	Yes	Yes	No
2010	Janssen et al. <sup>30</sup>	71	7.7	Acinar	6	30	Swelling	Unilateral	Left	Left	2.1	Yes	Yes	Yes	No
2013	Upchurch et al. <sup>31</sup>	78	1240	NA	NA	30	Swelling	Bilateral	Both	Both	NA	Yes	Yes	No	No
2010	Rahardjo et al. <sup>32</sup>	66	40	NA	NA	0	Swelling	Unilateral	Left	Left	NA	Yes	No	No	No
2007	Menchini-Fabris et al. <sup>33</sup>	67	15.5	Acinar	9	6	Pain	Unilateral	Left	Left	NA	Yes	No	No	No
2014	Kusaka et al. <sup>34</sup>	56	137	Acinar	9	64	Swelling	Unilateral	Right	Right	4.9	Yes	Yes	Yes	Yes
2022	Fortier et al. <sup>35</sup>	64	150	Ductal	8	264	Induration	Unilateral	Right	Right	40	Yes	Yes	Yes	No

PSA = prostate specific antigen; GS = Gleason Score; ADT = androgen deprivation therapy; RT = radiotherapy; CT = chemotherapy; NA = not available.

### CONFLICTING OF INTEREST STATEMENT

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### FUNDING

The authors received no financial support for the research, authorship, and/or publication of this article.

### AUTHORS' CONTRIBUTION

EMS, FPP and LG conceived the idea of this case report. UM, LR and DG provided clinical and radiological data. GDR and AT wrote the manuscript. LG, GDR and AT reviewed the manuscript. All authors contributed to the article and approved the submitted version.

### ETHICAL CONSIDERATION

We confirm that the local Ethics Committee has been consulted and that ethical approval is not necessary for the report of a single case.

### References

- Lorenzo L, Rogel R, Sanchez-Gonzalez JV, et al. Evaluation of Adult Acute Scrotum in the Emergency Room: Clinical Characteristics, Diagnosis, Management, and Costs. *Urology*. 2016;94:36-41. <https://doi.org/10.1016/j.urology.2016.05.018>. Epub 2016 May 19. PMID: 27210570.
- Kamble VR, Agrawal PM. Bilateral Testicular Metastases from Occult Primary Prostate Cancer in a Young Adult: A Rare Case Report. *J Clin Diagn Res*. 2017;11(5):TD03-TD05. <https://doi.org/10.7860/jcdr/2017/25292.9783>.
- Kiely G, Kavanagh L, Bolton D, et al. Urothelial carcinoma of the bladder with asynchronous metastases to both testes. *Urol Ann*. 2013;5(3):218-9. <https://doi.org/10.4103/0974-7796.115743>. PMID: 24049392; PMCID: PMC3764910.
- Migliari S, Sammartano A, Scarlattei M, et al. Development and Validation of a High-Pressure Liquid Chromatography Method for the Determination of Chemical Purity and Radiochemical Purity of a [<sup>68</sup>Ga-Labeled Glu-Urea-Lys(Ahx)-HBED-CC (Positron Emission Tomography) Tracer. *ACS Omega*. 2017;2(10):7120-7126. <https://doi.org/10.1021/acsomega.7b00677>. Epub 2017 Oct 25. PMID: 29520394; PMCID: PMC5837251.
- Gurel B, Ali TZ, Montgomery EA, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. *Am J Surg Pathol*. 2010;34(8):1097-105. <https://doi.org/10.1097/PAS.0b013e3181e6cbf3>. PMID: 20588175; PMCID: PMC3072223.
- Olorunsola IS, Etoneyaku AC, Lekwa BO, et al. Bilateral secondary testicular, epididymal and spermatic cords carcinoma of prostatic origin: a case report and review of the literature. *J Med Case Rep*. 2021;15(1):222. <https://doi.org/10.1186/s13256-021-02807-4>. PMID: 33931116; PMCID: PMC8088057.
- Chang J, Kwan B, Panjwani N, et al. Prostate adenocarcinoma metastases to the testis and brain: case report and review of the literature. *Oxf Med Case Reports*. 2017;2017(8):omx042. <https://doi.org/10.1093/omcr/omx042>. PMID: 28845236; PMCID: PMC5553064.
- Connelly ZM, Azzawe A, Flowers A, et al. Prostate cancer metastatic to bilateral testicles: case report and literature review. *Am J Clin Exp Uro*. 2021;9(2):182-188. PMID: 34079851; PMCID: PMC8165709.
- Bonetta A, Generali D, Corona SP, et al. Isolated Testicular Metastasis from Prostate Cancer. *Am J Case Rep*. 2017;18:887-889. <https://doi.org/10.12659/ajcr.904521>. PMID: 28804118; PMCID: PMC5567765.
- Ulbright TM, Tickoo SK, Berney DM, et al.; Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in testicular tumors: report from the International Society of Urological Pathology consensus conference. *Am J Surg Pathol*. 2014;38(8):e50-9. <https://doi.org/10.1097/PAS.000000000000233>. PMID: 24832161.
- Sandhu S, Moore CM, Chiong E, et al. Prostate cancer. *Lancet*. 2021;398(10305):1075-1090. [https://doi.org/10.1016/S0140-6736\(21\)00950-8](https://doi.org/10.1016/S0140-6736(21)00950-8). Epub 2021 Aug 6. PMID: 34370973.
- de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med*. 2020;382(22):2091-2102. <https://doi.org/10.1056/NEJMoa1911440>. Epub 2020 Apr 28. PMID: 32343890.
- Su J, Aslim EJ, Aydin H, et al. A rare case of isolated castrate resistant bilateral testicular metastases in advanced prostate cancer. *Asian J Urol*. 2018;5(2):127-130. <https://doi.org/10.1016/j.ajur.2017.03.001>. Epub 2017 Mar 8. PMID: 29736376; PMCID: PMC5934351.
- Hsieh TC, Lin CC, Kao CH, et al. Asymptomatic Solitary Metastasis to the Testis From Prostate Carcinoma Detected by FDG PET/CT. *Clin Nucl Med*. 2016;41(1):86-7. <https://doi.org/10.1097/RLU.0000000000001004>. PMID: 26402135.
- Manikandan R, Nathaniel C, Reeve N, Brough RJ. Bilateral testicular metastases from prostatic carcinoma. *Int J Urol*. 2006;13(4):476-7. <https://doi.org/10.1111/j.1442-2042.2006.01329.x>. PMID: 16734881.
- Santos-Lopes S, Lobo J, Henrique R, Oliveira J. Epididymal metastasis from prostate adenocarcinoma: An unusual and challenging diagnosis suspected in gallium-68 prostate-specific membrane antigen-positron emission tomography/computed tomography and histologically confirmed. *Urol Ann*. 2017;9(1):89-91. <https://doi.org/10.4103/0974-7796.198886>. PMID: 28216940; PMCID: PMC5308049.
- Sampathrajan S, Garg G, Gupta S, et al. Incidentally Detected Testicular Metastasis in a Case of Prostatic Adenocarcinoma. *J Clin Diagn Res*. 2015;9(12):ED03-4. <https://doi.org/10.7860/JC-DR/2015/15849.6884>. Epub 2015 Dec 1. PMID: 26816900; PMCID: PMC4717723.
- Bilal M, Uddin Z, Khan MA. Incidentally Found Metastatic Prostatic Carcinoma In A Therapeutic Orchiectomy Specimen. *J Ayub Med Coll Abbottabad*. 2019;31(1):129-130. PMID: 30868798.
- Dahiru AMC, Raheem N, Nggada HA, et al. Isolated testicular metastasis from prostatic adenocarcinoma. *Ann Afr Med*. 2019 Jul-Sep;18(3):173-175. [https://doi.org/10.4103/aam.aam\\_60\\_18](https://doi.org/10.4103/aam.aam_60_18). PMID: 31417019; PMCID: PMC6704808.
- Kato K, Kamei J, Yanase A, et al. Left testicular and pulmonary metastases of mucinous adenocarcinoma of the prostate after robot-assisted radical prostatectomy. *IJU Case Rep*. 2023 Apr 13;6(4):222-225. <https://doi.org/10.1002/iju5.12591>. PMID: 37405027; PMCID: PMC10315249.
- Baykal K, Yildirim S, Inal H, et al. Metastasis of prostate adenocarcinoma to testis. *Int J Urol*. 1997;4(1):104-5. <https://doi.org/10.1111/j.1442-2042.1997.tb00153.x>. PMID: 9179680.
- Aydogmus Y, Kilinc MF, Kabar M, et al. Metastasis of Prostate Adenocarcinoma to the Testis. *Urology*. 2015;86(1):206. <https://doi.org/10.1016/j.urology.2015.04.025>. PMID: 26142609.
- Campara Z, Simic D, Aleksic P, et al. Metastasis of Prostate Adenocarcinoma to the Testis. *Med Arch*. 2016;70(4):318-320. <https://doi.org/10.5455/medarh.2016.70.318-320>. PMID: 27703299; PMCID: PMC5035009.

- <sup>24</sup> Haupt B, Ro JY, Ayala AG, et al. Metastatic prostatic carcinoma to testis: histological features mimicking lymphoma. *Int J Clin Exp Pathol.* 2009;2(1):104-7. Epub 2008 May 10. PMID: 18830384; PMCID: PMC2491390.
- <sup>25</sup> Di Marco K, Johnson M, Esrig D, et al. Physical Examination Discovered Prostate Cancer Metastasis to the Testis: A Case Report. *Am J Case Rep.* 2022 Mar 15;23:e935521. <https://doi.org/10.12659/AJCR.935521>. PMID: 35288529; PMCID: PMC8935857.
- <sup>26</sup> Hermi A, Boussaffa H, Saadi A, et al. Prostate adenocarcinoma metastasis to the testis: A new case report. *Urol Case Rep.* 2023 Mar 27;48:102392. <https://doi.org/10.1016/j.eucr.2023.102392>. PMID: 37035722; PMCID: PMC10074503.
- <sup>27</sup> Gao Q, Chen J, Dai Y. Prostate cancer involving bilateral seminal vesicles along with bone and testicular metastases: a case report. *J Med Case Rep.* 2018;12(1):72. <https://doi.org/10.1186/s13256-017-1551-5>. PMID: 29519246; PMCID: PMC5844096.
- <sup>28</sup> Kim SO, Choi YD, Jung SI, et al. Prostate cancer with solitary metastases to the bilateral testis. *Yonsei Med J.* 2011 Mar;52(2):362-4. <https://doi.org/10.3349/ymj.2011.52.2.362>. PMID: 21319360; PMCID: PMC3051213.
- <sup>29</sup> Zhang J, Dong M, Hu X, et al. Prostatic adenocarcinoma presenting with metastases to the testis and epididymis: A case report. *Oncol Lett.* 2016;11(1):792-794. <https://doi.org/10.3892/ol.2015.3920>. Epub 2015 Nov 16. PMID: 26870285; PMCID: PMC4727079.
- <sup>30</sup> Janssen S, Bernhards J, Anastasiadis AG, et al. Solitary testicular metastasis from prostate cancer: a rare case of isolated recurrence after radical prostatectomy. *Anticancer Res.* 2010;30(5):1747-9. PMID: 20592373.
- <sup>31</sup> Upchurch EA, Khan F, Okeke A. Symptomatic bilateral testicular metastasis from carcinoma of the prostate. *BMJ Case Rep.* 2013;2013:bcr2013009008. <https://doi.org/10.1136/bcr-2013-009008>. PMID: 23563685; PMCID: PMC3645812.
- <sup>32</sup> Rahardjo HE, Umbas R, Sutisna H. Testicular metastases from prostate carcinoma. *Asian J Surg.* 2010;33(3):154-6. [https://doi.org/10.1016/S1015-9584\(10\)60026-7](https://doi.org/10.1016/S1015-9584(10)60026-7). PMID: 21163414.
- <sup>33</sup> Menchini-Fabris F, Giannarini G, Pomara G, et al. Testicular metastasis as isolated recurrence after radical prostatectomy. A first case. *Int J Impot Res.* 2007;19(1):108-9. <https://doi.org/10.1038/sj.ijir.3901460>. Epub 2006 Mar 23. PMID: 16554855.
- <sup>34</sup> Kusaka A, Koie T, Yamamoto H, et al. Testicular metastasis of prostate cancer: a case report. *Case Rep Oncol.* 2014;7(3):643-7. <https://doi.org/10.1159/000367779>. PMID: 25408658; PMCID: PMC4209256.
- <sup>35</sup> Fortier A, Mokadem S, Cornet E, et al. Testicular recurrence of oligometastatic prostatic adenocarcinoma after 22 years of androgen deprivation therapy. *Urol Case Rep.* 2022;43:102055. <https://doi.org/10.1016/j.eucr.2022.102055>. PMID: 35509726; PMCID: PMC9058943.